Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955893927> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2955893927 abstract "Introduction: We previously reported that FF-10832, a liposomal gemcitabine, exerted anti-tumor activity superior to that of gemcitabine with high stability, long plasma half-life, and preferential tumor accumulation in preclinical tumor models. Beneficial gemcitabine immune-modulating effects in tumor microenvironments have also been reported. We investigated the immune-modulating effects of FF-10832 by evaluating its anti-tumor activities combined with immune checkpoint blockade.Methods: Murine syngeneic tumor models were created by subcutaneous implantation of MBT-2 (bladder) or EMT6 (breast) tumor cells and tumor volume evaluated during and after treatments. Treatments included 2 or 4 mg/kg of FF-10832 or 240 mg/kg of gemcitabine intravenously once a week, and 10 mg/kg of an immune checkpoint inhibitor intraperitoneally twice a week for 3 weeks.Results: In the MBT-2 tumor model, although tumor growth was slightly inhibited by anti-PD-L1 mAb (clone: 10F.9G2) alone, only one out of nine mice showed complete response. Although FF-10832 decreased tumor growth during treatment (3 weeks), remission was incomplete, and tumor growth continued after treatment was discontinued. In contrast, in combination, tumor growth was inhibited even after treatment withdrawal; three out of nine mice achieved complete remission, and median survival improved (vehicle control and anti-PD-L1 mAb: 25 days; FF-10832: 28 days; combination: >49 days). This combination effect was comparable to that of gemcitabine combination. Previously, FF-10832 has also shown anti-tumor effects in a gemcitabine-insensitive BxPC-3 xenograft tumor model, so the potential benefit in combination with checkpoint inhibitors was evaluated in a gemcitabine-insensitive EMT6 tumor model. FF-10832 significantly inhibited tumor growth relative to that of gemcitabine in this model, but all mice showed tumor re-growth after treatment withdrawal. Anti-CTLA-4 mAb (clone: 9H10) alone showed complete response in only one out of eight mice. Strikingly, FF-10832 in combination with anti-CTLA-4 mAb exerted superior anti-tumor activity compared to that with gemcitabine, as shown by tumor regression in all mice and complete regression in seven out of eight mice. Further analysis to clarify the mode of action underlying the combination effect is ongoing now. These results indicate that the effect of immune checkpoint inhibitors is enhanced by FF-10832 regardless of tumor sensitivity to gemcitabine.Conclusion: Although immune checkpoint blockade is thought to be a breakthrough for cancer treatment, only a limited patient population has achieved favorable outcomes. Our results suggested that FF-10832 enhances the anti-tumor activity of immune checkpoint blockade, which could significantly improve treatment outcomes.Citation Format: Tadaaki Ioroi, Takashi Komori, Takeshi Matsumoto, Susumu Shimoyama, Takayuki Kobayashi, Hidetoshi Murao, Shinichi Watanabe, Shinji Hagiwara, Takefumi Hara. FF-10832 combined with immune checkpoint blockade shows favorable anti-tumor activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3953." @default.
- W2955893927 created "2019-07-12" @default.
- W2955893927 creator A5022926727 @default.
- W2955893927 creator A5033853574 @default.
- W2955893927 creator A5034279785 @default.
- W2955893927 creator A5044474821 @default.
- W2955893927 creator A5045153597 @default.
- W2955893927 creator A5047331091 @default.
- W2955893927 creator A5072424866 @default.
- W2955893927 creator A5072638113 @default.
- W2955893927 creator A5091709194 @default.
- W2955893927 date "2019-07-01" @default.
- W2955893927 modified "2023-10-18" @default.
- W2955893927 title "Abstract 3953: FF-10832 combined with immune checkpoint blockade shows favorable anti-tumor activity" @default.
- W2955893927 doi "https://doi.org/10.1158/1538-7445.sabcs18-3953" @default.
- W2955893927 hasPublicationYear "2019" @default.
- W2955893927 type Work @default.
- W2955893927 sameAs 2955893927 @default.
- W2955893927 citedByCount "0" @default.
- W2955893927 crossrefType "proceedings-article" @default.
- W2955893927 hasAuthorship W2955893927A5022926727 @default.
- W2955893927 hasAuthorship W2955893927A5033853574 @default.
- W2955893927 hasAuthorship W2955893927A5034279785 @default.
- W2955893927 hasAuthorship W2955893927A5044474821 @default.
- W2955893927 hasAuthorship W2955893927A5045153597 @default.
- W2955893927 hasAuthorship W2955893927A5047331091 @default.
- W2955893927 hasAuthorship W2955893927A5072424866 @default.
- W2955893927 hasAuthorship W2955893927A5072638113 @default.
- W2955893927 hasAuthorship W2955893927A5091709194 @default.
- W2955893927 hasConcept C121608353 @default.
- W2955893927 hasConcept C126322002 @default.
- W2955893927 hasConcept C126894567 @default.
- W2955893927 hasConcept C143998085 @default.
- W2955893927 hasConcept C170493617 @default.
- W2955893927 hasConcept C203014093 @default.
- W2955893927 hasConcept C2776694085 @default.
- W2955893927 hasConcept C2776999253 @default.
- W2955893927 hasConcept C2778468042 @default.
- W2955893927 hasConcept C2779256057 @default.
- W2955893927 hasConcept C2780258809 @default.
- W2955893927 hasConcept C2780851360 @default.
- W2955893927 hasConcept C502942594 @default.
- W2955893927 hasConcept C54355233 @default.
- W2955893927 hasConcept C552990157 @default.
- W2955893927 hasConcept C71924100 @default.
- W2955893927 hasConcept C81089528 @default.
- W2955893927 hasConcept C86803240 @default.
- W2955893927 hasConcept C8891405 @default.
- W2955893927 hasConceptScore W2955893927C121608353 @default.
- W2955893927 hasConceptScore W2955893927C126322002 @default.
- W2955893927 hasConceptScore W2955893927C126894567 @default.
- W2955893927 hasConceptScore W2955893927C143998085 @default.
- W2955893927 hasConceptScore W2955893927C170493617 @default.
- W2955893927 hasConceptScore W2955893927C203014093 @default.
- W2955893927 hasConceptScore W2955893927C2776694085 @default.
- W2955893927 hasConceptScore W2955893927C2776999253 @default.
- W2955893927 hasConceptScore W2955893927C2778468042 @default.
- W2955893927 hasConceptScore W2955893927C2779256057 @default.
- W2955893927 hasConceptScore W2955893927C2780258809 @default.
- W2955893927 hasConceptScore W2955893927C2780851360 @default.
- W2955893927 hasConceptScore W2955893927C502942594 @default.
- W2955893927 hasConceptScore W2955893927C54355233 @default.
- W2955893927 hasConceptScore W2955893927C552990157 @default.
- W2955893927 hasConceptScore W2955893927C71924100 @default.
- W2955893927 hasConceptScore W2955893927C81089528 @default.
- W2955893927 hasConceptScore W2955893927C86803240 @default.
- W2955893927 hasConceptScore W2955893927C8891405 @default.
- W2955893927 hasLocation W29558939271 @default.
- W2955893927 hasOpenAccess W2955893927 @default.
- W2955893927 hasPrimaryLocation W29558939271 @default.
- W2955893927 hasRelatedWork W1990619355 @default.
- W2955893927 hasRelatedWork W2080820783 @default.
- W2955893927 hasRelatedWork W2113566724 @default.
- W2955893927 hasRelatedWork W2287256905 @default.
- W2955893927 hasRelatedWork W2315587357 @default.
- W2955893927 hasRelatedWork W2582611731 @default.
- W2955893927 hasRelatedWork W3031098596 @default.
- W2955893927 hasRelatedWork W3033011894 @default.
- W2955893927 hasRelatedWork W3162226089 @default.
- W2955893927 hasRelatedWork W4309743026 @default.
- W2955893927 isParatext "false" @default.
- W2955893927 isRetracted "false" @default.
- W2955893927 magId "2955893927" @default.
- W2955893927 workType "article" @default.